Rintodestrant, developed by G1 therapeutics, demonstrated excellent safety and tolerability in a Phase II clinical trial (NCT03455270) as a monotherapy and in combination with palbociclib in ER+/HER2− advanced BC patients with ESR1 mutations (354, 355). This evidence concerns the gene ERBB2 and breast cancer.